Cargando…

Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer

BACKGROUND: Family with sequence similarity 234 member B (FAM234B), a protein-coding gene, is mainly expressed in brain tissues. Its clinical significance and biological function in tumors, especially in breast cancer (BC), have not been elucidated. METHODS: We firstly investigated the expression pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Lijuan, Wang, Meng, Zheng, Yi, Tian, Tian, Deng, Yujiao, Xu, Peng, Lin, Shuai, Yang, Si, Zhou, Linghui, Hao, Qian, Wu, Ying, Dai, Zhijun, Kang, Huafeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721111/
https://www.ncbi.nlm.nih.gov/pubmed/33299353
http://dx.doi.org/10.2147/CMAR.S280009
_version_ 1783619976135966720
author Lyu, Lijuan
Wang, Meng
Zheng, Yi
Tian, Tian
Deng, Yujiao
Xu, Peng
Lin, Shuai
Yang, Si
Zhou, Linghui
Hao, Qian
Wu, Ying
Dai, Zhijun
Kang, Huafeng
author_facet Lyu, Lijuan
Wang, Meng
Zheng, Yi
Tian, Tian
Deng, Yujiao
Xu, Peng
Lin, Shuai
Yang, Si
Zhou, Linghui
Hao, Qian
Wu, Ying
Dai, Zhijun
Kang, Huafeng
author_sort Lyu, Lijuan
collection PubMed
description BACKGROUND: Family with sequence similarity 234 member B (FAM234B), a protein-coding gene, is mainly expressed in brain tissues. Its clinical significance and biological function in tumors, especially in breast cancer (BC), have not been elucidated. METHODS: We firstly investigated the expression pattern of FAM234B at the mRNA and protein levels using Oncomine, TCGA portal, GEPIA, TIMER, HPA, and UALCAN databases, then applied bc-GenExMiner to assess the associations between expression level of FAM234B and clinicopathological features of BC. Besides, we also verified the expression of FAM234B expression in clinical BC samples using qRT-PCR. Subsequently, GEPIA, bc-GenExMiner, and TIMER databases were used to analyze the prognostic significance of FAM234B in all BC and different molecular subtypes. Finally, we conducted co-expression analysis and gene set enrichment analysis (GSEA). Additionally, we explored the regulatory mechanism of FAM234B in BC. RESULTS: Both bioinformatics analysis and experimental verification confirmed that the FAM234B expression was significantly higher at the mRNA and protein levels in luminal BC tissues than in adjacent normal tissues. High FAM234B expression was significantly correlated with older age, estrogen receptor-positive, progesterone receptor-positive, human epidermal growth factor receptor 2-negative, wild-type p53, low Nottingham prognostic index, low Scarff-Bloom-Richardson grade, lymph node metastasis positivity, and high tumor stage. Moreover, survival analysis indicated that high FAM234B expression was significantly related to a worse prognosis in patients with luminal BC. GSEA indicated that FAM234B was positively related to membrane transport process and negatively associated with immune response function. Besides, mechanism exploration indicated that pseudogene HTR7P1 might act as endogenous RNA to compete with has-miR-1271-5p or has-miR-381-3p for binding to FAM234B, thereby upregulating the expression of FAM234B in luminal BC. CONCLUSION: Our results suggest that FAM234B may be a candidate therapeutic target or prognostic marker for luminal breast cancer.
format Online
Article
Text
id pubmed-7721111
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77211112020-12-08 Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer Lyu, Lijuan Wang, Meng Zheng, Yi Tian, Tian Deng, Yujiao Xu, Peng Lin, Shuai Yang, Si Zhou, Linghui Hao, Qian Wu, Ying Dai, Zhijun Kang, Huafeng Cancer Manag Res Original Research BACKGROUND: Family with sequence similarity 234 member B (FAM234B), a protein-coding gene, is mainly expressed in brain tissues. Its clinical significance and biological function in tumors, especially in breast cancer (BC), have not been elucidated. METHODS: We firstly investigated the expression pattern of FAM234B at the mRNA and protein levels using Oncomine, TCGA portal, GEPIA, TIMER, HPA, and UALCAN databases, then applied bc-GenExMiner to assess the associations between expression level of FAM234B and clinicopathological features of BC. Besides, we also verified the expression of FAM234B expression in clinical BC samples using qRT-PCR. Subsequently, GEPIA, bc-GenExMiner, and TIMER databases were used to analyze the prognostic significance of FAM234B in all BC and different molecular subtypes. Finally, we conducted co-expression analysis and gene set enrichment analysis (GSEA). Additionally, we explored the regulatory mechanism of FAM234B in BC. RESULTS: Both bioinformatics analysis and experimental verification confirmed that the FAM234B expression was significantly higher at the mRNA and protein levels in luminal BC tissues than in adjacent normal tissues. High FAM234B expression was significantly correlated with older age, estrogen receptor-positive, progesterone receptor-positive, human epidermal growth factor receptor 2-negative, wild-type p53, low Nottingham prognostic index, low Scarff-Bloom-Richardson grade, lymph node metastasis positivity, and high tumor stage. Moreover, survival analysis indicated that high FAM234B expression was significantly related to a worse prognosis in patients with luminal BC. GSEA indicated that FAM234B was positively related to membrane transport process and negatively associated with immune response function. Besides, mechanism exploration indicated that pseudogene HTR7P1 might act as endogenous RNA to compete with has-miR-1271-5p or has-miR-381-3p for binding to FAM234B, thereby upregulating the expression of FAM234B in luminal BC. CONCLUSION: Our results suggest that FAM234B may be a candidate therapeutic target or prognostic marker for luminal breast cancer. Dove 2020-12-03 /pmc/articles/PMC7721111/ /pubmed/33299353 http://dx.doi.org/10.2147/CMAR.S280009 Text en © 2020 Lyu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lyu, Lijuan
Wang, Meng
Zheng, Yi
Tian, Tian
Deng, Yujiao
Xu, Peng
Lin, Shuai
Yang, Si
Zhou, Linghui
Hao, Qian
Wu, Ying
Dai, Zhijun
Kang, Huafeng
Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer
title Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer
title_full Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer
title_fullStr Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer
title_full_unstemmed Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer
title_short Overexpression of FAM234B Predicts Poor Prognosis in Patients with Luminal Breast Cancer
title_sort overexpression of fam234b predicts poor prognosis in patients with luminal breast cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721111/
https://www.ncbi.nlm.nih.gov/pubmed/33299353
http://dx.doi.org/10.2147/CMAR.S280009
work_keys_str_mv AT lyulijuan overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT wangmeng overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT zhengyi overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT tiantian overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT dengyujiao overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT xupeng overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT linshuai overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT yangsi overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT zhoulinghui overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT haoqian overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT wuying overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT daizhijun overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer
AT kanghuafeng overexpressionoffam234bpredictspoorprognosisinpatientswithluminalbreastcancer